Cargando…

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyauchi, Eisaku, Morita, Satoshi, Nakamura, Atsushi, Hosomi, Yukio, Watanabe, Kana, Ikeda, Satoshi, Seike, Masahiro, Fujita, Yuka, Minato, Koichi, Ko, Ryo, Harada, Toshiyuki, Hagiwara, Koichi, Kobayashi, Kunihiko, Nukiwa, Toshihiro, Inoue, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	CLINICAL TRIAL UPDATES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622660/ https://www.ncbi.nlm.nih.gov/pubmed/35960896 http://dx.doi.org/10.1200/JCO.21.02911

Ejemplares similares

Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations
por: Oizumi, Satoshi, et al.
Publicado: (2018)

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study
por: Fukuhara, Tatsuro, et al.
Publicado: (2020)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
por: Watanabe, Satoshi, et al.
Publicado: (2014)

Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1
por: Nakahara, Yoshiro, et al.
Publicado: (2016)

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
por: Minegishi, Yuji, et al.
Publicado: (2021)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Peritoneal and meningeal relapse from lung adenocarcinoma after a response to gefitinib: A case report
por: KURISHIMA, KOICHI, et al.
Publicado: (2013)

Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
por: Nishimura, Yukio
Publicado: (2018)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

Rhabdomyolysis Caused by Gefitinib Overdose
por: Obayashi, Shohei, et al.
Publicado: (2021)

Gefitinib: Dermatitis: case report
Publicado: (2022)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
por: Mimori, Tomoyasu, et al.
Publicado: (2022)

Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B
por: Noro, Rintaro, et al.
Publicado: (2020)

Trichoscopic Findings of Erosive Pustular Dermatosis of the Scalp Associated with Gefitinib
por: Fukui, Tomohisa, et al.
Publicado: (2017)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Alitretinoin Treatment for Gefitinib-Induced Paronychia
por: Lee, Soo Young, et al.
Publicado: (2019)

A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol
por: Asao, Tetsuhiko, et al.
Publicado: (2022)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

A Case of Cutaneous Infection Caused by Mycobacterium Szulgai with Progression to Acute Respiratory Distress Syndrome
por: Ohta, Hiromitsu, et al.
Publicado: (2011)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

The cytotoxicity of gefitinib on patient‑derived induced pluripotent stem cells reflects gefitinib‑induced liver injury in the clinical setting
por: Fujisaka, Yasuhito, et al.
Publicado: (2023)

Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
por: Miyauchi, Eisaku, et al.
Publicado: (2017)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
por: Stoppoloni, Daniela, et al.
Publicado: (2010)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line
por: Yan, Dong, et al.
Publicado: (2015)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
por: Azuma, Koichi, et al.
Publicado: (2014)

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
por: Nishimura, Yukio, et al.
Publicado: (2019)

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells
por: Zhu, Yinsong, et al.
Publicado: (2015)

M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR
por: Xiao, Fengqi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j5uel0f6cmp8pj46ip6ir46jrd